The Contribution of Untreated and Treated Anxiety and Depression to Prenatal, Intrapartum, and Neonatal Outcomes
Overview
Authors
Affiliations
To determine independent perinatal associations of anxiety and depression in women who were and were not treated with psychotropic drugs in comparison to unaffected pregnancies. From 2013 to 2014, 978 (6.3%) cases of anxiety/depression, of which 35% used psychotropic drugs, were compared with 14,514 (93.7%) unaffected pregnancies using logistic regression. Subjects were more likely to be Non-Hispanic Whites, use tobacco and illegal substances, be unmarried, use public insurance, and have medical complications of pregnancy. For independent maternal outcomes, untreated anxiety/depression was associated with labor induction (adjusted odds ratio [aOR] = 2.02), cesarean deliveries (aOR = 1.69), longer length of stay (aOR = 1.96), readmission (aOR = 2.40), fever (aOR = 2.03), magnesium exposure (aOR = 1.82), and postpartum hemorrhage (aOR = 2.57), whereas treated cases were associated with increased blood transfusion (aOR = 4.81), severe perineal lacerations (aOR = 2.93), and postpartum hemorrhage (aOR = 3.85), but decreased risk of cesarean deliveries (aOR = 0.59). Independent neonatal outcomes included small for gestational age (aOR = 3.04), meconium-stained fluid (aOR = 1.85; 2.61), respiratory failure (aOR = 5.84), neonatal adaptation syndrome (aOR = 11; 10.2), and neonatal seizures (aOR = 12.3) in treated cases, whereas untreated cases were associated with hypoxia (aOR = 2.83), low Apgar score (aOR = 3.82), and encephalopathy (aOR = 18.3). Exposure to multiple psychotropic medications independently increased the risk of neonatal adaptation syndrome, neonatal length of stay, and hypoglycemia. Untreated cases were associated with increased maternal adverse outcomes, whereas treated cases were associated with more adverse neonatal outcomes when compared with unaffected pregnancies.
Societal costs of untreated perinatal mood and anxiety disorders in Vermont.
Platt I, Pendl-Robinson E, Dehus E, ONeil S, Vohra D, Kenny M Arch Womens Ment Health. 2024; 27(4):585-594.
PMID: 38321244 DOI: 10.1007/s00737-024-01429-1.
Hall S, Zivin K, Dalton V, Bell S, Kolenic G, Admon L Gen Hosp Psychiatry. 2023; 85:126-132.
PMID: 37866105 PMC: 10897524. DOI: 10.1016/j.genhosppsych.2023.10.006.
Takelle G, Nakie G, Rtbey G, Melkam M Front Psychiatry. 2023; 14:1148638.
PMID: 37415690 PMC: 10322208. DOI: 10.3389/fpsyt.2023.1148638.
Haryalchi K, Kazemi Aski S, Ghanaie M, Fotouhi M, Mansoori R, Sadraei S Health Sci Rep. 2023; 6(5):e1282.
PMID: 37216059 PMC: 10199455. DOI: 10.1002/hsr2.1282.
Confounding by Indication in Studies of Selective Serotonin Reuptake Inhibitors.
Lee J, Chang S Psychiatry Investig. 2022; 19(11):873-883.
PMID: 36444151 PMC: 9708863. DOI: 10.30773/pi.2022.0209.